RAD51 as a potential biomarker and therapeutic target for pancreatic cancer

Nagaraj Nagathihalli, Ganesh Nagaraju

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Chemotherapy is a very important therapeutic strategy for cancer treatment. The failure of conventional and molecularly targeted chemotherapeutic regimes for the treatment of pancreatic cancer highlights a desperate need for novel therapeutic interventions. Chemotherapy often fails to eliminate all tumor cells because of intrinsic or acquired drug resistance, which is the most common cause of tumor recurrence. Overexpression of RAD51 protein, a key player in DNA repair/recombination has been observed in many cancer cells and its hyperexpression is implicated in drug resistance. Recent studies suggest that RAD51 overexpression contributes to the development, progression and drug resistance of pancreatic cancer cells. Here we provide a brief overview of the available pieces of evidence in support of the role of RAD51 in pancreatic tumorigenesis and drug resistance, and hypothesize that RAD51 could serve as a potential biomarker for diagnosis of pancreatic cancer. We discuss the possible involvement of RAD51 in the drug resistance associated with epithelial to mesenchymal transition and with cancer stem cells. Finally, we speculate that targeting RAD51 in pancreatic cancer cells may be a novel approach for the treatment of pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)209-218
Number of pages10
JournalBiochimica et Biophysica Acta - Reviews on Cancer
Volume1816
Issue number2
DOIs
StatePublished - Dec 2011
Externally publishedYes

Fingerprint

Pancreatic Neoplasms
Drug Resistance
Biomarkers
Neoplasms
Rad51 Recombinase
Therapeutics
Drug Therapy
Epithelial-Mesenchymal Transition
Neoplastic Stem Cells
DNA Repair
Genetic Recombination
Carcinogenesis
Recurrence

Keywords

  • Biomarker
  • DNA repair
  • Drug resistance
  • Genome instability
  • Pancreatic cancer
  • RAD51

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Genetics

Cite this

RAD51 as a potential biomarker and therapeutic target for pancreatic cancer. / Nagathihalli, Nagaraj; Nagaraju, Ganesh.

In: Biochimica et Biophysica Acta - Reviews on Cancer, Vol. 1816, No. 2, 12.2011, p. 209-218.

Research output: Contribution to journalArticle

@article{ad642f9bf389460ea9dd3ec50e76dd3f,
title = "RAD51 as a potential biomarker and therapeutic target for pancreatic cancer",
abstract = "Chemotherapy is a very important therapeutic strategy for cancer treatment. The failure of conventional and molecularly targeted chemotherapeutic regimes for the treatment of pancreatic cancer highlights a desperate need for novel therapeutic interventions. Chemotherapy often fails to eliminate all tumor cells because of intrinsic or acquired drug resistance, which is the most common cause of tumor recurrence. Overexpression of RAD51 protein, a key player in DNA repair/recombination has been observed in many cancer cells and its hyperexpression is implicated in drug resistance. Recent studies suggest that RAD51 overexpression contributes to the development, progression and drug resistance of pancreatic cancer cells. Here we provide a brief overview of the available pieces of evidence in support of the role of RAD51 in pancreatic tumorigenesis and drug resistance, and hypothesize that RAD51 could serve as a potential biomarker for diagnosis of pancreatic cancer. We discuss the possible involvement of RAD51 in the drug resistance associated with epithelial to mesenchymal transition and with cancer stem cells. Finally, we speculate that targeting RAD51 in pancreatic cancer cells may be a novel approach for the treatment of pancreatic cancer.",
keywords = "Biomarker, DNA repair, Drug resistance, Genome instability, Pancreatic cancer, RAD51",
author = "Nagaraj Nagathihalli and Ganesh Nagaraju",
year = "2011",
month = "12",
doi = "10.1016/j.bbcan.2011.07.004",
language = "English (US)",
volume = "1816",
pages = "209--218",
journal = "Biochimica et Biophysica Acta - Reviews on Cancer",
issn = "0304-419X",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - RAD51 as a potential biomarker and therapeutic target for pancreatic cancer

AU - Nagathihalli, Nagaraj

AU - Nagaraju, Ganesh

PY - 2011/12

Y1 - 2011/12

N2 - Chemotherapy is a very important therapeutic strategy for cancer treatment. The failure of conventional and molecularly targeted chemotherapeutic regimes for the treatment of pancreatic cancer highlights a desperate need for novel therapeutic interventions. Chemotherapy often fails to eliminate all tumor cells because of intrinsic or acquired drug resistance, which is the most common cause of tumor recurrence. Overexpression of RAD51 protein, a key player in DNA repair/recombination has been observed in many cancer cells and its hyperexpression is implicated in drug resistance. Recent studies suggest that RAD51 overexpression contributes to the development, progression and drug resistance of pancreatic cancer cells. Here we provide a brief overview of the available pieces of evidence in support of the role of RAD51 in pancreatic tumorigenesis and drug resistance, and hypothesize that RAD51 could serve as a potential biomarker for diagnosis of pancreatic cancer. We discuss the possible involvement of RAD51 in the drug resistance associated with epithelial to mesenchymal transition and with cancer stem cells. Finally, we speculate that targeting RAD51 in pancreatic cancer cells may be a novel approach for the treatment of pancreatic cancer.

AB - Chemotherapy is a very important therapeutic strategy for cancer treatment. The failure of conventional and molecularly targeted chemotherapeutic regimes for the treatment of pancreatic cancer highlights a desperate need for novel therapeutic interventions. Chemotherapy often fails to eliminate all tumor cells because of intrinsic or acquired drug resistance, which is the most common cause of tumor recurrence. Overexpression of RAD51 protein, a key player in DNA repair/recombination has been observed in many cancer cells and its hyperexpression is implicated in drug resistance. Recent studies suggest that RAD51 overexpression contributes to the development, progression and drug resistance of pancreatic cancer cells. Here we provide a brief overview of the available pieces of evidence in support of the role of RAD51 in pancreatic tumorigenesis and drug resistance, and hypothesize that RAD51 could serve as a potential biomarker for diagnosis of pancreatic cancer. We discuss the possible involvement of RAD51 in the drug resistance associated with epithelial to mesenchymal transition and with cancer stem cells. Finally, we speculate that targeting RAD51 in pancreatic cancer cells may be a novel approach for the treatment of pancreatic cancer.

KW - Biomarker

KW - DNA repair

KW - Drug resistance

KW - Genome instability

KW - Pancreatic cancer

KW - RAD51

UR - http://www.scopus.com/inward/record.url?scp=80051576726&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051576726&partnerID=8YFLogxK

U2 - 10.1016/j.bbcan.2011.07.004

DO - 10.1016/j.bbcan.2011.07.004

M3 - Article

C2 - 21807066

AN - SCOPUS:80051576726

VL - 1816

SP - 209

EP - 218

JO - Biochimica et Biophysica Acta - Reviews on Cancer

JF - Biochimica et Biophysica Acta - Reviews on Cancer

SN - 0304-419X

IS - 2

ER -